Terms: = Endocrine gland cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Treatment
452 results:
1. Efficacy and safety of pd-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis.
Chen Y; Liu X; Hu Y; Xia L
Medicine (Baltimore); 2024 May; 103(18):e38019. PubMed ID: 38701316
[TBL] [Abstract] [Full Text] [Related]
2. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
Fu W; Feng Q; Tao R
Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
[TBL] [Abstract] [Full Text] [Related]
3. PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report.
Kong YH; Xu ML; Zhang JJ; Chen GQ; Hong ZH; Zhang H; Dai XX; Ma YF; Zhao XR; Zhang CY; Chen RZ; Xing PF; Zhang LY
World J Gastroenterol; 2024 Mar; 30(9):1237-1249. PubMed ID: 38577174
[TBL] [Abstract] [Full Text] [Related]
4. Circulating tumor-associated antigen-specific IFNγ
Murakami H; Takahama S; Akita H; Kobayashi S; Masuta Y; Nagatsuka Y; Higashiguchi M; Tomokuni A; Yoshida K; Takahashi H; Doki Y; Eguchi H; Matsuura N; Yamamoto T
Front Immunol; 2024; 15():1363568. PubMed ID: 38550601
[TBL] [Abstract] [Full Text] [Related]
5. A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions.
Enzler T; Shi J; McGue J; Griffith BD; Sun L; Sahai V; Nathan H; Frankel TL
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474199
[TBL] [Abstract] [Full Text] [Related]
6. Chronic Lymphocytic Thyroiditis with Oncocytic Metaplasia Influences PD-L1 Expression in Papillary Thyroid Carcinoma.
Santana VB; Krüger VM; Abrahão MCY; Cantú PLM; Brackmann RL; Pandolfi GM; Marisco LS; Remonatto G; Ferreira LA; Graudenz MS
Head Neck Pathol; 2024 Mar; 18(1):14. PubMed ID: 38457034
[TBL] [Abstract] [Full Text] [Related]
7. 4-Hydroxyphenylpyruvate Dioxygenase-Like predicts the prognosis and the immunotherapy response of cancers: a pan-cancer analysis.
Li H; Liu J; Wang S; Xu Y; Tang Q; Ying G
Aging (Albany NY); 2024 Mar; 16(5):4327-4347. PubMed ID: 38451188
[TBL] [Abstract] [Full Text] [Related]
8. Case report: Diverse immune responses in advanced pancreatic ductal adenocarcinoma treated with immune checkpoint inhibitor-based conversion therapies.
Li X; Xiao C; Li R; Zhang P; Yang H; Cao D
Front Immunol; 2024; 15():1326556. PubMed ID: 38415262
[TBL] [Abstract] [Full Text] [Related]
9. A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way.
Balar PC; Apostolopoulos V; Chavda VP
Eur J Pharmacol; 2024 Apr; 969():176451. PubMed ID: 38408598
[TBL] [Abstract] [Full Text] [Related]
10. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.
Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y
Front Immunol; 2024; 15():1228235. PubMed ID: 38404588
[TBL] [Abstract] [Full Text] [Related]
11. Periostin is associated with prognosis and immune cell infiltration in pancreatic adenocarcinoma based on integrated bioinformatics analysis.
Chen Y; Zhang F; Zhang B; Trojanowicz B; Hämmerle M; Kleeff J; Sunami Y
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1990. PubMed ID: 38389400
[TBL] [Abstract] [Full Text] [Related]
12. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells.
Wang J; Gai J; Zhang T; Niu N; Qi H; Thomas DL; Li K; Xia T; Rodriguez C; Parkinson R; Durham J; McPhaul T; Narang AK; Anders RA; Osipov A; Wang H; He J; Laheru DA; Herman JM; Lee V; Jaffee EM; Thompson ED; Zhu Q; Zheng L
Sci Adv; 2024 Feb; 10(6):eadk1827. PubMed ID: 38324679
[TBL] [Abstract] [Full Text] [Related]
13. Effect of sodium stibogluconate in recruiting and awakening immune cells in the pleural fluid of pancreatic cancer: preparation for immunotherapy.
Yu B; Jing P; Gao F; Zhang P; Zheng G; Zhang X
Front Immunol; 2023; 14():1315468. PubMed ID: 38313432
[TBL] [Abstract] [Full Text] [Related]
14. Advance in the role of chemokines/chemokine receptors in carcinogenesis: Focus on pancreatic cancer.
Song N; Cui K; Zeng L; Li M; Fan Y; Shi P; Wang Z; Su W; Wang H
Eur J Pharmacol; 2024 Mar; 967():176357. PubMed ID: 38309677
[TBL] [Abstract] [Full Text] [Related]
15. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Voissière A; Gomez-Roca C; Chabaud S; Rodriguez C; Nkodia A; Berthet J; Montane L; Bidaux AS; Treilleux I; Eberst L; Terret C; Korakis I; Garin G; Pérol D; Delord JP; Caux C; Dubois B; Ménétrier-Caux C; Bendriss-Vermare N; Cassier PA
Sci Transl Med; 2024 Jan; 16(731):eadd1834. PubMed ID: 38266104
[TBL] [Abstract] [Full Text] [Related]
16. Characteristics and immune checkpoint status of radioiodine-refractory recurrent papillary thyroid carcinomas from Ukrainian Chornobyl Tissue Bank donors.
Bogdanova T; Rogounovitch TI; Zurnadzhy L; Mitsutake N; Tronko M; Ito M; Bolgov M; Chernyshov S; Gulevatyi S; Masiuk S; Yamashita S; Saenko VA
Front Endocrinol (Lausanne); 2023; 14():1343848. PubMed ID: 38260161
[TBL] [Abstract] [Full Text] [Related]
17. Metabolic-Related Gene Prognostic Index for Predicting Prognosis, Immunotherapy Response, and Candidate Drugs in Ovarian cancer.
Guo S; Liu Y; Sun Y; Zhou H; Gao Y; Wang P; Zhi H; Zhang Y; Gan J; Ning S
J Chem Inf Model; 2024 Feb; 64(3):1066-1080. PubMed ID: 38238993
[TBL] [Abstract] [Full Text] [Related]
18. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF
Hamidi S; Iyer PC; Dadu R; Gule-Monroe MK; Maniakas A; Zafereo ME; Wang JR; Busaidy NL; Cabanillas ME
Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606
[No Abstract] [Full Text] [Related]
19. A Microfluidics Approach for Ovarian cancer Immune Monitoring in an Outpatient Setting.
Libbrecht S; Vankerckhoven A; de Wijs K; Baert T; Thirion G; Vandenbrande K; Van Gorp T; Timmerman D; Coosemans A; Lagae L
Cells; 2023 Dec; 13(1):. PubMed ID: 38201211
[TBL] [Abstract] [Full Text] [Related]
20. Successful immunotherapy with pd-1 Iinhibitor for advanced pancreatic cancer: report of two cases and review of literature.
Qiu L; Liu C; Li H
Anticancer Drugs; 2024 Mar; 35(3):263-270. PubMed ID: 38194502
[TBL] [Abstract] [Full Text] [Related]
[Next]